Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
| Image |  |
|---|---|
| Description | scientific article published on 16 May 2011 |
| Author/s |
author: Thomas Burmeister Thorsten Raff Oliver Ottmann Gerhard Zugmaier Hermann Einsele Monika Brüggemann Dieter Hoelzer Nicola Gökbuget Patrick A. Baeuerle |
| Publication date | May 16, 2011 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |